GaBI Journal-Generics and Biosimilars Initiative Journal
Impact Factor Trend (2023–2026)
Clarivate IF trend for GaBI Journal-Generics and Biosimilars Initiative Journal
SCImago Journal Rank citation prestige weighting
16 papers with at least that number of citations each
Aims & Scope
The scope of GaBI Journal is broad and of interest and relevance to professionals active in clinical practice, pharmaceutical science and policy. Materials published in GaBI Journal include high quality research reports, literature reviews and case studies, all of which are peer reviewed. Manuscripts on all aspects of generic and biosimilar medicines, covering areas in clinical, fundamental, technical, manufacturing, bi-processing, economic and social aspects of pharmaceuticals and therapeutics are welcome. In addition, high quality work submitted in other formats, for example, scientific and evidence-based commentaries, may also be considered. In all cases, the emphasis is on quality, originality and knowledge contribution to those involved in health care. All manuscripts submitted to GaBI Journal are subject to a rigorous peer review process. GaBI Journal plans to be indexed in PubMed within two years, and that indexing will be retrospective. GaBI Journal is published quarterly from 2012. All articles are published in English.
Special Issues
Calls for PapersNo active Calls for Papers found for this journal.
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
PHARMACOLOGY & PHARMACY
PHARMACOLOGY & PHARMACY
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
SCImago & Scopus Journal Intelligence
Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact
Weighted prestige citation metric per document indexed in the Scopus database.
Average citations received per document published in the 2-year window.
Estimated Article Processing Charge for Open Access publication.
Scopus 3-Year Publication & Citation Window
Aggregated from Scopus database across the 3-year SJR evaluation window.
Societal Impact & Inclusivity (SCImago)
Citations in government and international policy documents
Percentage of female authors published in the journal
Real-world societal policy reach and author gender diversity tracked by SCImago.
Scopus Subject Categories
Journal Metrics & Citation Visualizations
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Academic Intelligence Overview & Context
ImpaQ AnalysisGaBI Journal-Generics and Biosimilars Initiative Journal (ISSN: 2033-6403) is a peer-reviewed international scholarly journal in the field of PHARMACOLOGY & PHARMACY, published by Pro Pharma Communications International in Belgium. The periodical holds a Journal Impact Factor (JIF) of 0.30, ranking in quartile Q4 of Web of Science (ESCI), a Scopus SJR indicator of 0.224 (Q1), an H-index of 16.
The journal enforces rigorous peer evaluation with an annual output of approximately 1 scientific articles. In terms of accessibility and author fees, it operates under the Subscription model with an estimated APC of $2,408 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics